Policy Tracker · Patient Lens · September 26, 2026
Keeping weight off after semaglutide may need a second drug
A new trial targets what happens after the shots stop, when the pounds tend to come back.
Key details
- A Minnesota bill would let pharmacies add flavoring to compounded GLP-1 drugs without triggering stricter pharmacy compounding rules.
- A new Phase 2 trial is recruiting people who lost weight on semaglutide to test whether the drug ALV-100 helps maintain that loss.
On Friday, September 25, 2026, two developments touched people who use or are considering GLP-1 drugs for weight loss. One involves how these medications are made and dispensed. The other involves what happens after the weight loss itself, once treatment ends. Together they point to the same reality: staying on a GLP-1 drug, or moving off one, involves choices that go beyond the prescription itself.
The Minnesota bill addresses a narrow but practical problem. Compounded GLP-1 drugs can have a taste or texture that makes them hard to tolerate, and pharmacies that want to add a flavoring agent currently risk being treated as if they were compounding a new drug altogether, subject to more demanding rules. SF 3783 would carve out an exemption so that adding flavor alone does not trigger that stricter oversight. For patients who rely on compounded versions of these medications, that could mean easier access to a product they can actually take consistently, without the compounding pharmacy having to clear a higher regulatory bar just to make the drug more palatable.
The ALV-100 trial speaks to a different kind of problem, one that appears after treatment seems to have worked. Many people who lose weight on semaglutide regain some or all of it once they stop the drug, and researchers are now recruiting participants for a Phase 2 study to test whether ALV-100 can help maintain that loss instead. The trial is open specifically to people who already achieved weight loss on semaglutide, rather than to new users starting treatment. If the drug proves effective, it could offer a way to preserve results without staying on semaglutide indefinitely, though that remains to be tested rather than assumed.
If you take a compounded GLP-1 drug in Minnesota, it may be worth following SF 3783 as it moves through the legislature, since its outcome could affect the version of the drug you're able to get. If you lost weight on semaglutide and are concerned about regaining it, you may want to look into whether the ALV-100 trial is enrolling near you and whether you meet its criteria. Neither development changes anything about your current treatment plan today, and any decision about switching drugs or joining a trial should be made with your prescriber. Keep an eye on both stories as they develop, since a bill still needs to pass and a Phase 2 trial is still early in testing.
By Amanda Bonello